RxDoctor Payments Data

Kirk Gavlick, DO

Cardiovascular Disease · Tucson, AZNPI 1669434619

Payments from drug & device makers

$1,925in general payments, 2019–2025

Across 190 payments — averaging $10.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$824
  • Pfizer$217
  • Cvrx, Inc.$140
  • Kowa Pharmaceuticals America, Inc.$135
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$107
  • Amgen$85
  • plus $417 from 13 others

What the payments were for

  • Food & beverage$1,925100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,925 in reported general payments places this provider in the 40th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$203,140
Medicare patients
803
Services billed
2,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban408$538,157
XareltoRivaroxaban125$155,402
Repatha SureclickEvolocumab117$120,365
EntrestoSacubitril/Valsartan28$47,488
MultaqDronedarone Hcl11$24,876
JardianceEmpagliflozin16$13,319
Ranolazine ErRanolazine87$9,033
Flecainide Acetate103$5,410
Losartan Potassium499$5,045
Atorvastatin Calcium468$4,384
Midodrine Hcl57$3,789
Amiodarone Hcl200$3,735
Potassium Chloride226$3,225
Furosemide423$2,937
Nebivolol Hcl32$2,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$217$538,157408 claims
Johnson & JohnsonXarelto$62$155,402125 claims
NovartisEntresto$34$47,48828 claims
Sanofi-aventis U.S. LLCMultaq$16$24,87611 claims
Boehringer IngelheimJardiance$24$13,31916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →